BP
BCRX icon

Ballentine Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Ballentine Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change % 		Capital Flow Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,951
Closed -$77.1K – 606
2023
Q2 		$77.1K Buy
+10,951
New +$77.1K ﹤0.01% 592